VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis (Q38462868)

3 September 2017

0 references

1 reference

title

VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis (English)

1 reference

3 September 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947646%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Marcelo Rocha Cruz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947646%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Gilberto de Lima Lopes

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947646%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Joao Paulo da Silveira Nogueira Lima

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947646%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

7 May 2015

1 reference

Breast Cancer Research and Treatment

3 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947646%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

151

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947646%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947646%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

481-489

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947646%20AND%20SRC:MED&resulttype=core&format=json

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

10 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

A systematic review of bevacizumab efficacy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Avastin Hearing Leads to More Uncertainty Over Drug's Future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Making genuine progress against metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Fighting fire with fire: rekindling the bevacizumab debate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Reputation and precedent in the bevacizumab decision

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Multidimensional challenges in clinical drug development, regulatory approval, and marketing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Markers of response for the antiangiogenic agent bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Biomarkers and surrogate end points--the challenge of statistical validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3410-7